Table 1:
Baseline Demographic and Clinical Characteristics.
| Characteristics | Tesamorelin (N = 193) | Placebo (N = 148) | P Value |
|---|---|---|---|
| Age (years) | 47.8 (7.3) | 48 (7.6) | 0.79 |
| Male (%) | 89.1 | 83.8 | 0.15 |
| Race (%) | 0.10 | ||
| White | 86.0 | 78.4 | |
| Black or African American | 9.3 | 11.5 | |
| Others | 4.7 | 10.1 | |
| Use of lipid lowering treatment (%) | 52.8 | 43.9 | 0.10 |
| Use of testosterone (%) | 24.9 | 17.6 | 0.10 |
| Body mass index (kg/m2) | 28.9 (4.2) | 28.6 (4.3) | 0.60 |
| Waist circumference (cm) | 105.1 (9.6) | 104.1 (8.2) | 0.32 |
| CD4+ T cell count (cells/μL) | 563.0 (400.0–774.0) | 560.0 (416.0–785.0) | 0.72 |
| Time since HIV diagnosis (months) | 178.4 (122.6–217.9) | 155.9 (115.7–205.3) | 0.06 |
| ART duration (months) | 49.5 (29.2–82.2) | 48.2 (28.3–73.4) | 0.28 |
| ART type | 0.65 | ||
| NNRTI + NRTI | 32% | 35% | |
| NNRTI + PI _ NRTI | 7% | 9% | |
| PI + NRTI | 48% | 48% | |
| NRTI only | 6% | 4% | |
| Other | 7% | 4% | |
| VAT area (cm2) | 197.0 (86.2) | 188.7 (84.8) | 0.38 |
| VAT density (HU) | −91.2 (8.8) | −91.4 (8.9) | 0.80 |
| SAT area (cm2) | 217.6 (119.3) | 228.6 (122.3) | 0.41 |
| SAT density (HU) | −94.1 (10.7) | −95.3 (10.9) | 0.29 |
Data are presented as mean (SD) or median (IQR) for continuous measures, and % for categorical measures. ART=antiretroviral therapy, NNRTI= non-nuceloside reverse transcriptase inhibitor, NRTI=nucleoside reverse transcriptase inhibitor, PI=protease inhibitor, VAT=visceral adipose tissue, SAT=subcutaneous adipose tissue, HU=Hounsfield Units